Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PVST). Etripamil is an
The nasal spray etripamil showed promise in treatment of the irregular heartbeat condition PSVT. The drug was twice as likely to resolve
the efficacy and safety of self-administration of etripamil versus placebo nasal spray in patients with PSVT 156 subjects experienced a vagal maneuver-refractory, symptomatic episode of confirmed PSVT; 107 subjects self-administered etripamil and 49 administered placebo nasal spray with 2:1 randomization (Figure 1).
The purpose of this study is to evaluate the safety of etripamil nasal spray in patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients will be
Etripamil nasal spray is being developed for self-administration by patients for the treatment of paroxysmal supraventricular tachycardia.
Etripamil nasal spray, an investigational treatment, would be the etripamil nasal spray in emergency-department patients experiencing AFib-RVR
etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Per the FDA, the NDA for etripamil to treat PSVT
Apomorphine, a non-ergoline dopamine agonist, is believed to siteName MPR siteURL siteID 7 Etripamil Nasal Spray
Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.
Comments